Scholarlink

<p>Studies have shown that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) provide lung benefits beyond glycemic control, including reduced risks of lung malignancy, pulmonary infection and chronic obstructive pulmonary disease exacerbations. A retrospective cohort study with a new-user and active-comparator design was conducted using the TriNetX US Network. Adults (≥ 18 years) with Type 2 diabetes mellitus (T2DM) (<i>n</i> = 3,389,059) from January 1, 2005, to December 31, 2020, were identified. Two cohorts of new GLP-1 RA (<i>n</i> = 201,153) and new dipeptidyl peptidase-4 inhibitor (DPP4i) (<i>n</i> = 323,114) users were created. Propensity score matching was used to create comparable cohorts. The primary outcome was lung cancer, while other pulmonary conditions were secondary outcomes over a 10-year follow-up. Through 1:1 propensity score matching, two balanced cohorts of GLP-1 RA and DPP4i (<i>n</i> = 158,224) users were created. GLP-1 RA users had a significantly lower risk of lung cancer than did DPP4i users (hazard ratios [HR] 0.86; 95% confidence interval [CI] 0.80–0.94). Reduced risk of influenza and pneumonia (HR 0.94; 95% CI 0.92–0.96) and pulmonary fibrosis (HR 0.92; 95% CI 0.87–0.98) were also noted in GLP-1 RA users. Our findings indicate that GLP-1 RAs may lower the risks of lung cancer, pulmonary fibrosis, and respiratory infections, meriting further prospective study.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Association between glucagon-like peptide-1 receptor agonist therapy and respiratory illness in patients with type 2 diabetes: a retrospective observational cohort study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月13日

查看全文
  • Li-Ti Ho,
  • Yu-Wei Fang,
  • Pei-Sung Hsu,
  • Jing-Tong Wang,
  • Ming-Hsien Tsai

摘要

Studies have shown that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) provide lung benefits beyond glycemic control, including reduced risks of lung malignancy, pulmonary infection and chronic obstructive pulmonary disease exacerbations. A retrospective cohort study with a new-user and active-comparator design was conducted using the TriNetX US Network. Adults (≥ 18 years) with Type 2 diabetes mellitus (T2DM) (n = 3,389,059) from January 1, 2005, to December 31, 2020, were identified. Two cohorts of new GLP-1 RA (n = 201,153) and new dipeptidyl peptidase-4 inhibitor (DPP4i) (n = 323,114) users were created. Propensity score matching was used to create comparable cohorts. The primary outcome was lung cancer, while other pulmonary conditions were secondary outcomes over a 10-year follow-up. Through 1:1 propensity score matching, two balanced cohorts of GLP-1 RA and DPP4i (n = 158,224) users were created. GLP-1 RA users had a significantly lower risk of lung cancer than did DPP4i users (hazard ratios [HR] 0.86; 95% confidence interval [CI] 0.80–0.94). Reduced risk of influenza and pneumonia (HR 0.94; 95% CI 0.92–0.96) and pulmonary fibrosis (HR 0.92; 95% CI 0.87–0.98) were also noted in GLP-1 RA users. Our findings indicate that GLP-1 RAs may lower the risks of lung cancer, pulmonary fibrosis, and respiratory infections, meriting further prospective study.